Fra Q2 rapporten.
"Preclinical publication in high-impact immunology journalPreclinical results were recently published in the high-impact immunology journal “Frontiers in Immunology” (Combined Photosensitation and vaccination enable CD8 T-Cell Immunity and Tumor Suppression independent of CD4 T-Cellhelp, Varypataki et al. Front.Immunol. 10:1548). The study provided evidence of strong activation of CD8 T-cells and tumour regression after vaccination with fimaVACCin melanoma bearing mice, including mice with impaired T-helper cell function. The studythereby demonstrate that therapeutic cancer vaccination with fimaVACCcan be effective independent of T-helper cell functionality. "
" PCI Facilitates CD8 T Cell-Priming Independent of CD40-CD40L Signaling
CD40L on CD4 T cells may interact with CD40 on APCs and thereby provide co-stimulatory signals that help effective priming of CD8 T cells. Since PCI enabled CD8 T-cell activation in the absence of CD4 T cells, we tested whether CD40 signaling was dispensable in PCI-based immunization. To this end, CD40L-deficient mice were immunized. Neither proliferation nor IFN-γ production (Figure 1G) of SIINFEKL-specific CD8 T cells depended on CD40-signaling when immunization was combined with PCI. In immunized mice that were not PCI treated, the responses in WT and CD40L ko mice were comparably low. These results suggest that the PCI-facilitated priming of antigen-specific CD8 T cells takes place independent of CD40.
PCI-Based Vaccination Prevents Subsequent Growth of Mouse Melanoma Independent of MHC Class II Signaling"
Noe nytt stort som kommer innenfor fimaVACC?
